Caricamento...
Severe infusion reaction due to nivolumab: A case report
BACKGROUND: Nivolumab is an anti‐PD1 immune checkpoint inhibitor commonly used for the treatment of solid organ and hematological malignancies. Severe infusion reaction due to nivolumab is quite rare. CASE: We report a case of severe infusion reaction due to nivolumab necessitating ICU admission and...
Salvato in:
| Pubblicato in: | Cancer Rep (Hoboken) |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7941420/ https://ncbi.nlm.nih.gov/pubmed/32671983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1246 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|